A DNAzyme which cleaves EGR-1 mRNA

A DNAzyme which can specifically cleave EGR-1 mRNA comprises a catalytic domain which cleaves mRNA at a purine: pyrimidine cleavage site, a first binding domain contiguous with the 5' end of the catalytic domain and a second binding domain contiguous with the 3' end of the catalytic domain...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	BAKER, ANDREW R, ATKINS, DAVID G, KHACHIGIAN, LEVON MICHAEL
Format:	Patent
Sprache:	eng
Schlagworte:	BANDAGES, DRESSINGS OR ABSORBENT PADS BEER BIOCHEMISTRY CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, ORSURGICAL ARTICLES CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF,TUBULAR STRUCTURES OF THE BODY, E.G. STENTS DISINFECTION, STERILISATION, OR DEODORISATION OF AIR ENZYMOLOGY FILTERS IMPLANTABLE INTO BLOOD VESSELS FIRST-AID KITS FOMENTATION HUMAN NECESSITIES HYGIENE MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICALARTICLES MEDICAL OR VETERINARY SCIENCE METALLURGY METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS INGENERAL MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS PROSTHESES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS TREATMENT OR PROTECTION OF EYES OR EARS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A DNAzyme which can specifically cleave EGR-1 mRNA comprises a catalytic domain which cleaves mRNA at a purine: pyrimidine cleavage site, a first binding domain contiguous with the 5' end of the catalytic domain and a second binding domain contiguous with the 3' end of the catalytic domain. The binding domains are sufficiently complementary to the two regions immediately flanking a purine: pyrimidine cleavage site within the region of EGR-1 mRNA corresponding to nucleotides 168 to 332 in SEQ ID NO: 1, such that the DNAzyme cleaves the EGR-1 mRNA. Also described are pharmaceutical compositions comprising the DNAzyme which are useful in inhibiting EGR-1 activity in cells and for inhibiting proliferation or migration of cells. The cell proliferation or migration conditions can be post-angioplasty restenosis, vein graft failure, hypertension, transplant coronary disease and complications associated with atherosclerosis or peripheral vascular disease. An angioplastic stent can be coated with a dose of DNAzyme for inhibiting the onset of restenosis.